Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | AGXT | P21549 | 1/20 | 0.53 |
| ▸ | KMO | O15229 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LGMN | Q99538 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1529196 | 0.84 | AGXT (0.49) | LMNAAGXTMAPTHTTMEN1 | |
| SCHEMBL1529262 | 0.82 | AGXT (0.47) | LMNAAGXTMAPTHTTMEN1 | |
| SCHEMBL1825155 | 0.82 | MAPT (0.50) | LMNAMAPTHTTMEN1NPC1 | |
| SCHEMBL27329825 | 0.81 | LMNA (0.71) | LMNAAGXTKMOMAPTHTT | |
| SCHEMBL4834394 | 0.81 | ADRB1 (0.65) | LMNAAGXTKMOMAPTMEN1 | |
| SCHEMBL20627137 | 0.81 | LMNA (0.55) | LMNAAGXTKMOMAPTHTT | |
| SCHEMBL2599616 | 0.79 | ADRA2C (0.59) | AGXTMAPTHTTNPC1ALDH1A1 | |
| Nitrogen SCHEMBL8429553 | 0.78 | ADRB1 (0.61) | LMNAAGXTKMOMAPTMEN1 | |
| SCHEMBL25493030 | 0.77 | ALDH1A1 (0.54) | LMNAAGXTKMOHTTMEN1 | |
| SCHEMBL12129236 | 0.77 | KDM4E (0.59) | LMNAAGXTKMOMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119552120-A | Pyrazole and imidazole compounds for inhibiting IL-17 and rory | 里亚塔医药公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-112654610-B | Pyrazole and imidazole compounds for inhibiting IL-17 and rory | 里亚塔医药公司 | 2024-12-24 | — | — | CN | disclosed |
| CN-118660875-A | Protein tyrosine phosphatase inhibitors, compositions, and methods of use | 百时美施贵宝公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-118515663-A | Imidazopyridine or imidazopyrazine compounds, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-112654610-A | Pyrazole and imidazole compounds for inhibiting IL-17 and ROR gamma | 里亚塔医药公司 | 2021-04-13 | — | — | CN | disclosed |
| EP-3197895-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-03-11 | — | — | EP | disclosed |
| US-10004724-B2 | Compounds alpha v beta 6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| EP-3197895-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046241-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
| EP-2571872-B1 | COMPOUNDS | TREHERNE JOHNATHAN MARK (GB) | 2014-12-31 | — | — | EP | disclosed |
| EP-2571872-A1 | COMPOUNDS | BTG International Limited (GB) | 2013-03-27 | — | — | EP | disclosed |
| EP-2571856-A1 | COMPOUNDS | BTG International Limited (GB) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011144577-A1 | COMPOUNDS | SENEXIS LIMITED (GB) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011144578-A1 | COMPOUNDS | SENEXIS LIMITED (GB) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004724-B2 | Compounds alpha v beta 6 integrin antagonists | ITGAV, ITGB6, ITGB1 | LMNA 2882/4885AGXT 4792/4885KMO 4813/4885 |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | ITGAV, ITGB6, ITGB1 | LMNA 3680/4885AGXT 4808/4885KMO 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.